RLAY Valuation

Relay Therapeutics Inc

Add to Watchlist

Advanced Chart

3.795

+0.115(3.125%)1D

Overview
Forecast
Valuation
Earnings

RLAY Relative Valuation

RLAY's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, RLAY is overvalued; if below, it's undervalued.

Historical Valuation

Relay Therapeutics Inc (RLAY) is now in the Fair zone, suggesting that its current forward PS ratio of 110.47 is considered Fairly compared with the five-year average of -8.64. The fair price of Relay Therapeutics Inc (RLAY) is between to according to relative valuation methord.

Relative Value

Fair Zone

Current Price：3.67

Fair

Trailing

Forward

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

0.90

P/B

Median3y

1.57

Median5y

2.50

-42.86

FCF Yield

Median3y

-25.98

Median5y

-16.76

Competitors Valuation Multiple

The average P/S ratio for RLAY's competitors is 116.88, providing a benchmark for relative valuation. Relay Therapeutics Inc Corp (RLAY) exhibits a P/S ratio of 110.47, which is -5.48% above the industry average. Given its robust revenue growth of -23.26%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

RLAY.O

Relay Therapeutics Inc

110.47

Average P/S: 116.88

-23.26%